These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 25674933)

  • 1. Saroglitazar for the treatment of dyslipidemia in diabetic patients.
    Joshi SR
    Expert Opin Pharmacother; 2015 Mar; 16(4):597-606. PubMed ID: 25674933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.
    Kaul U; Parmar D; Manjunath K; Shah M; Parmar K; Patil KP; Jaiswal A
    Cardiovasc Diabetol; 2019 Jun; 18(1):80. PubMed ID: 31208414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial.
    Jain N; Bhansali S; Kurpad AV; Hawkins M; Sharma A; Kaur S; Rastogi A; Bhansali A
    Sci Rep; 2019 Dec; 9(1):19017. PubMed ID: 31831868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).
    Krishnappa M; Patil K; Parmar K; Trivedi P; Mody N; Shah C; Faldu K; Maroo S; ; Parmar D
    Cardiovasc Diabetol; 2020 Jun; 19(1):93. PubMed ID: 32560724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia.
    Balakumar P; Mahadevan N; Sambathkumar R
    Curr Mol Pharmacol; 2019; 12(3):195-201. PubMed ID: 30636619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.
    Honda A; Kamata S; Satta C; Machida Y; Uchii K; Terasawa K; Nemoto A; Oyama T; Ishii I
    Biol Pharm Bull; 2021; 44(9):1210-1219. PubMed ID: 34471049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Observational study of effects of Saroglitazar on glycaemic and lipid parameters on Indian patients with type 2 diabetes.
    Chatterjee S; Majumder A; Ray S
    Sci Rep; 2015 Jan; 5():7706. PubMed ID: 25573251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Rastogi A; Dunbar RL; Thacker HP; Bhatt J; Parmar K; Parmar DV
    Acta Diabetol; 2020 Jul; 57(7):809-818. PubMed ID: 32030508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI).
    Jani RH; Pai V; Jha P; Jariwala G; Mukhopadhyay S; Bhansali A; Joshi S
    Diabetes Technol Ther; 2014 Feb; 16(2):63-71. PubMed ID: 24138536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients.
    Shetty SR; Kumar S; Mathur RP; Sharma KH; Jaiswal AD
    Indian Heart J; 2015; 67(1):23-6. PubMed ID: 25820046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.
    Goldstein BJ; Rosenstock J; Anzalone D; Tou C; Ohman KP
    Curr Med Res Opin; 2006 Dec; 22(12):2575-90. PubMed ID: 17166340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis.
    Siddiqui MS; Parmar D; Sheikh F; Sarin SK; Cisneros L; Gawrieh S; Momin T; Duseja A; Sanyal AJ
    Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2597-2605.e2. PubMed ID: 36731585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
    Gawrieh S; Noureddin M; Loo N; Mohseni R; Awasty V; Cusi K; Kowdley KV; Lai M; Schiff E; Parmar D; Patel P; Chalasani N
    Hepatology; 2021 Oct; 74(4):1809-1824. PubMed ID: 33811367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
    Tonstad S; Retterstøl K; Ose L; Ohman KP; Lindberg MB; Svensson M
    Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease.
    Kumar DP; Caffrey R; Marioneaux J; Santhekadur PK; Bhat M; Alonso C; Koduru SV; Philip B; Jain MR; Giri SR; Bedossa P; Sanyal AJ
    Sci Rep; 2020 Jun; 10(1):9330. PubMed ID: 32518275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis.
    Akbari R; Behdarvand T; Afarin R; Yaghooti H; Jalali MT; Mohammadtaghvaei N
    BMC Pharmacol Toxicol; 2021 Oct; 22(1):53. PubMed ID: 34593018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of Saroglitazar in Treatment Of Pre-diabetes with Dyslipidemia: STOP-D.
    Bhosle D; Bhosle V; Bobde J; Bhagat A; Shaikh H; Kadam R
    J Assoc Physicians India; 2018 Mar; 66(3):14-7. PubMed ID: 30341861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation of saroglitazar magnesium, a dual PPAR-α/γ agonist for treatment of dyslipidemia and metabolic disorders.
    Patel H; Giri P; Patel P; Singh S; Gupta L; Patel U; Modi N; Shah K; Jain MR; Srinivas NR; Patel P
    Xenobiotica; 2018 Dec; 48(12):1268-1277. PubMed ID: 29224415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.